Millennium Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-36,533
| Closed | -$38K | – | 6649 |
|
|
2023
Q3 | $38K | Sell |
36,533
-18,062
| -33% | -$24.5K | ﹤0.01% | 5537 |
|
|
2023
Q2 | $77K | Sell |
54,595
-90,752
| -62% | -$130K | ﹤0.01% | 5385 |
|
|
2023
Q1 | $231K | Sell |
145,347
-53,557
| -27% | -$97.3K | ﹤0.01% | 5088 |
|
|
2022
Q4 | $290K | Buy |
198,904
+48,530
| +32% | +$142K | ﹤0.01% | 5128 |
|
|
2022
Q3 | $642K | Sell |
150,374
-165,935
| -52% | -$703K | ﹤0.01% | 4733 |
|
|
2022
Q2 | $1.23M | Buy |
+316,309
| New | +$901K | ﹤0.01% | 4192 |
|
|
2021
Q3 | – | Sell |
-27,932
| Closed | -$317K | – | 7356 |
|
|
2021
Q2 | $317K | Sell |
27,932
-95,478
| -77% | -$958K | ﹤0.01% | 5681 |
|
|
2021
Q1 | $1.14M | Buy |
+123,410
| New | +$1.29M | ﹤0.01% | 4093 |
|
|
2020
Q4 | – | Sell |
-5,931
| Closed | -$26 | – | 5674 |
|
|
2020
Q3 | $26 | Buy |
+5,931
| New | +$51.8K | ﹤0.01% | 4334 |
|
|
2020
Q1 | – | Sell |
-5,508
| Closed | -$65K | – | 4630 |
|
|
2019
Q4 | $65K | Sell |
5,508
-6,728
| -55% | -$113K | ﹤0.01% | 4072 |
|
|
2019
Q3 | $308K | Buy |
+12,236
| New | +$353K | ﹤0.01% | 3554 |
|
|
2018
Q2 | – | Sell |
-3,046
| Closed | -$290K | – | 4262 |
|
|
2018
Q1 | $290K | Buy |
3,046
+2,607
| +594% | +$447K | ﹤0.01% | 3234 |
|
|
2017
Q4 | $57K | Buy |
439
+56
| +15% | +$5.25K | ﹤0.01% | 3713 |
|
|
2017
Q3 | $26K | Hold |
383
| – | – | ﹤0.01% | 3438 |
|
|
2017
Q2 | $36K | Sell |
383
-8
| -2% | -$918 | ﹤0.01% | 3373 |
|
|
2017
Q1 | $56K | Buy |
+391
| New | +$55.9K | ﹤0.01% | 3374 |
|
|
2016
Q3 | – | Sell |
-88
| Closed | -$10K | – | 3688 |
|
|
2016
Q2 | $10K | Buy |
+88
| New | +$9.75K | ﹤0.01% | 3114 |
|
|
2015
Q4 | – | Sell |
-564
| Closed | -$96K | – | 3835 |
|
|
2015
Q3 | $96K | Sell |
564
-6,021
| -91% | -$2.17M | ﹤0.01% | 3280 |
|
|
2015
Q2 | $4.16M | Buy |
6,585
+300
| +5% | +$159K | 0.01% | 1502 |
|
|
2015
Q1 | $3.23M | Buy |
6,285
+2,547
| +68% | +$1.28M | 0.01% | 1661 |
|
|
2014
Q4 | $2M | Buy |
3,738
+3,381
| +947% | +$1.52M | ﹤0.01% | 1970 |
|
|
2014
Q3 | $536K | Sell |
357
-1,284
| -78% | -$1.86M | ﹤0.01% | 2701 |
|
|
2014
Q2 | $2.25M | Buy |
1,641
+367
| +29% | +$426K | 0.01% | 1690 |
|
|
2014
Q1 | $1.77M | Sell |
1,274
-1,768
| -58% | -$2.06M | 0.01% | 1870 |
|
|
2013
Q4 | $3.03M | Buy |
3,042
+130
| +4% | +$134K | 0.01% | 1526 |
|
|
2013
Q3 | $3.03M | Sell |
2,912
-3,822
| -57% | -$4.08M | 0.01% | 1434 |
|
|
2013
Q2 | $7.33M | Buy |
+6,734
| New | +$7.5M | 0.02% | 799 |
|
Other funds holding VIRX
BI
SB
LCM
MCM
ACM
Millennium Management's VIRX Position: Q4 2023 in Review
Millennium Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2023, closing a stake of 36,533 shares — an estimated $38K sold.
Millennium Management first reported a position in VIRX in Q2 2013 and held it in 27 quarters. The position peaked at $7.33M in Q2 2013. 42 funds tracked by Wall St. Rank hold VIRX as of Q4 2023.
- Millennium Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Millennium Management sold 36,533 Viracta Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $38K.
- Millennium Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 27 quarters.
- Millennium Management's Viracta Therapeutics, Inc. Common Stock position peaked at $7.33M in Q2 2013.
- 42 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2023.
Based on Millennium Management's 13F filing for Q4 2023, filed 14 Feb 2024.